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Abstract
This review discusses evidence for population-based screening with contemporary
screening tools. In Europe, prostate-specific antigen (PSA)-based screening led to a rel-
ative reduction of prostate cancer (PCa) mortality, but also to a substantial amount of
overdiagnosis and unnecessarily biopsies. Risk stratification based on a single variable
(a clinical variable or based on the presence of a lesion on prostate imaging) or based
on multivariable approaches can aid in reducing unnecessary prostate biopsies and
overdiagnosis by selecting men who can benefit from further clinical assessment. Mul-
tivariable approaches include clinical variables, and biomarkers, often combined in risk
calculators or nomograms. These risk calculators can also incorporate the result of
MRI imaging. In general, as compared to a purely PSA based approach, the combina-
tion of relevant prebiopsy information results in superior selection of men at higher
risk of harboring clinically significant prostate cancer. Currently, it is not possible to
draw any conclusions on the superiority of these multivariable risk-based approaches
since head-to-head comparisons are virtually lacking. Recently initiated large
population-based screening studies in Finland, Germany and Sweden, incorporating
various multivariable risk stratification approaches will hopefully give more insight in
whether the harm-benefit ratio can be improved, that is, maintain (or improving) the
ability to reduce metastatic disease and prostate cancer mortality while reducing harm
caused by unnecessary testing and overdiagnosis including related overtreatment.
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1 | PROSTATE-SPECIFIC ANTIGEN-BASED
SCREENING, ONE SIZE FITS ALL
In the mid-1990s a decrease in prostate cancer (PCa) mortality was
observed.1-3 This reduction can be attributed to both advances in
treatment modalities and early detection, that is, prostate-specific
antigen (PSA) testing. A modeling study showed that the rate of PCa
mortality would increase without PSA testing while it would decrease
with PSA testing.4 PSA testing accounted for 45% to 70% of the
reduction in PCa mortality, implying an improvement in PCa-specific
survival and more favorable tumor characteristics in PCa cases
detected with PSA testing. The effect of PSA-based screening and
PCa specific mortality was evaluated in several randomized trials. One
of such randomized trials, the European Randomized Study of Screen-
ing for Prostate Cancer (ERSPC), demonstrated with a follow-up of
16 years a 20% relative PCa mortality reduction in favor of men
screened, translating in an absolute difference in PCa mortality of
approximately 18 less PCa deaths per 10 000 men screened.5 To pre-
vent one man dying of PCa, 570 men needed to be invited for screen-
ing, and as compared to a no-screening situation 18 additional PCa
cases needed to be diagnosed. The above numbers relate to the
intention-to-treat analysis, adjusting for noncompliance and PSA con-
tamination (screening in the control arm) showed an even larger PCa
mortality reduction in favor of screening ranging from 22% to 32%
within different ERSPC centers.6-8
The counterpart of the ERSPC in the United States (the Prostate
Lung, Colorectal and Ovarian Cancer Screening Trial [PLCO]) did not
show a reduction in PCa mortality.9 However, this trial was criticized
due to the high PSA contamination in the control arm.10-13 Modeling
studies suggest that with higher biopsy compliance and less contami-
nation in the PLCO trial, it would most likely showed comparable
results to the ERSPC trial.10,14
The ERSPC study also confirmed the hypothesis that with
active screening more cancer would be detected.5,12,15,16 It must
however be noted that a lot of these screen-detected cancers were
low-grade tumors defined as Gleason 3 + 3 or International Society
of Urological Pathology (ISUP) grade group 1 PCa cases that, due to
their very low potential of causing harm to the patient can be con-
sidered as being overdiagnosed. The rate of overdiagnosis has been
estimated based on lead time (ie, the time that screening advances
diagnosis compared to the time of the diagnosis without screening),
the excess incidence between screened men and nonscreened men,
and the presence of low-grade tumor on either biopsy, radical pros-
tatectomy or autopsy.17 These different approaches resulted in
estimates of rates of overdiagnosis between 1.7% and 67% for men
with screen-detected PCa. To elaborate, based on radical prosta-
tectomy studies the rate of overdiagnosis ranged from 2% up to
47% and from autopsy studies the rate of overdiagnosis ranged
from 19% to 43%. In a small pilot study of ERSPC Rotterdam with
currently a median follow-up of 19 years a total of 55% of the diag-
noses in the screening arm were graded as Gleason 3 + 3 (ISUP
grade group 1), of which a considerable part can safely be consid-
ered as overdiagnosis.18
From the long-running and high-quality ERSPC study,19 several
lessons could be learned. The relative PCa mortality reduction of 20%
was only observed when applying multiple screening interventions,20
potentially explaining why no reduction in PCa mortality was
observed in the Cluster Randomized Trial of PSA Testing for Prostate
Cancer (CAP) trial.21 PSA-based screening is associated with a consid-
erable rate of overdiagnosis, unnecessary PSA testing (only 23% of all
PSA measurements were considered as a positive test) and unneces-
sary biopsies (only 24% of all prostate biopsies triggered by an ele-
vated PSA level were positive).5 So, while the data support the fact
that there are life-threatening prostate cancers that with early detec-
tion and subsequent treatment can be cured or inhibited in their pro-
gression the way to selectively identify those cancers remains subject
of many ongoing research projects worldwide. Taken into account all
data above showing that some—but not all—men can benefit of
screening and the fact that this screening coincides with high rates of
overdiagnosis strongly suggests that the “one size fits all” approach
does not hold for PSA-based screening.
The European Association of Urology (EAU) recently published a
statement in which they favor PSA-based screening, but with a critical
note that overdiagnosis, unnecessary testing and overtreatment
should be reduced.22 The goal of nowadays PSA-based screening (eg,
PSA tests at the general practitioner) should be in detecting the can-
cers that have the potential to metastasize or to grow outside the
prostatic gland. In other words, PSA-based screening should not be
aimed at detecting as much as PCa as possible but selectively focus
on detecting those cancers that can harm if left undetected and
untreated. This reduction in unnecessary testing, overdiagnosis and
coinciding subsequent overtreatment could be achieved with person-
alized risk stratification with the aim to identify those men that will
very likely benefit from screening.
2 | HOW SHOULD WE SCREEN TO KEEP
THE BENEFIT AND REDUCE THE HARM
2.1 | Risk stratification
Risk stratification is a method to quantify the risk that a patient has
for the event of interest, for example, the probability of detecting PCa
or clinically significant (cs)PCa on prostate biopsy. In this review, we
defined csPCa as Gleason 3 + 4 or ISUP grade group 2 and indicated
if otherwise defined in the study discussed in this review. The goal of
risk stratification is to select only those men that are considered to
have an increased risk for further assessment with often (more) inva-
sive procedures. However, it is essential to differentiate between
population-based screening studies and studies in the clinical, daily
practice setting (often referred to as opportunistic screening). The
latter type of screening starts with risk stratification at, for exam-
ple, the general practitioner and often include PSA but certainly
also other characteristics like urinary complains and comorbidities.
Subsequently, after referral to the urologist a second risk stratifica-
tion is often done leading to a higher risk population as compared
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to the population-based setting as described in the currently avail-
able literature. In these population-based trials, all men within a
certain age range are invited and then risk stratified on the basis of
only PSA. Those with elevated PSA are immediately eligible for
biopsy resulting in a population with a lower a priori (before biopsy)
risk on having PCa (and csPCa) as compared to the population
referred for biopsy in the opportunistic/clinical setting. More con-
temporary population-based screening studies now include addi-
tional risk stratification tools to increase this a priori risk and will
be discussed in a separate section of this manuscript.
The result of the risk stratification process can be used in the deci-
sion making process in the form of a so-called decision aid where indi-
vidually calculated probabilities are presented with recommendations
on how to continue. Available research has shown that the implementa-
tion of decision aids in clinical practice lead to improved decision qual-
ity.23-26 A simple risk stratification in the pathway potentially leading to
the detection of csPCa can be achieved by assessing a single PSA mea-
surement at age 40 to 5527 or at age 60.28 For example, applying a cut-
off for further assessment (detection and treatment) for men aged
60 with a first PSA > 1.06 ng/mL could potentially have avoided 91%
of all metastatic disease that surfaced during the 25 year observation
period (missing 0.37% of the total of 3.7% of men that were diagnosed
with metastatic disease over 25 year). A total of 95% of all deathly
cases could have been detected earlier (missing 0.15% of the total of
3.0% of men dying of PCa over 25 year). At the same time this data
suggest that men aged 60 with a PSA level ≤ 1 ng/mL could refrain
from any further screening since the probability of being confronted
with a life-threatening PCa is low. Another study showed that the
13-year cumulative incidence for csPCa of men aged 55 to 60 with a
first PSA between 0.50 and 0.99 ng/mL was as low as 1.5%, which
increased to 5.4% for men with a first PSA between 1.00 and 1.99 ng/
mL. These data also suggest that men within this age category and a
PSA < 1.00 ng/mL are at very low risk of harboring csPCa and could
consider to refrain from further screening.29 In addition, other studies
investigating PSA kinetics, for example, PSA velocity, in the field of early
detection could not confirm that PSA kinetics were more predictive
than the absolute level for the diagnosis of PCa.30-32
Next to risk stratification based on a single clinical variable, multi-
variable model-based approaches estimate the relation between rele-
vant clinical variables and the outcome (eg, PCa on biopsy) for men
with clinical suspicion of PCa. There are numerous of these so-called
prediction models to detect csPCa.33-35 The difference between all
predictions models is the selection of (clinical) variables. However, for
the generalizability of a prediction model, it is essential to test the per-
formance of the model outside the development setting. This so-
called external validation is often lacking.34,36,37 Two well-validated
risk calculators which are also being recommended by the EAU38,39
are the Rotterdam Prostate Cancer Risk Calculator (RPCRC)40,41 and
the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC)
2.0.32,42,43 For the RPCRC, data of the Dutch part of the ERSPC study
were used to develop a model to predict the presence of PCa at pros-
tate biopsy using data of relevant clinical prebiopsy variables.44 In this
model, PSA and prostate volume were the strongest predictors for the
detection of PCa, followed by digital rectal examination (DRE) and
transrectal ultrasonography (TRUS). However, models should differen-
tiate between men with prior biopsy or without previous biopsy as it
was demonstrated that the relation between PSA level and the pres-
ence of PCa is different in men with a prior biopsy.45 These findings
are combined in the RPCRC to allow individualized predictions for the
probability of detecting PCa and csPCa at biopsy.40,41 This individual
risk-based strategy as compared to a strategy of biopsying all with a
PSA ≥ 3.0 ng/mL showed a reduction of 33% of all biopsies for men
biopsied for the first time while 14% of all PCa and 7% of all csPCa
would not be detected.41 For men with previous biopsy, 37% of biop-
sies would be avoided while 16% of all PCa and 9% all csPCa would
not have been detected. Next to the RPCRC, another widely used
prediction model is the risk calculator from the PCPTRC 2.0.32 This
risk calculator calculates the probability of finding no PCa, any PCa,
and csPCa based on PSA, age, race, family history of PCa, DRE and
the presence of a previous biopsy. An external validation of these two
risk calculators did not show much difference for the prediction of
csPCa: the RPCRC showed a slightly better discrimination and a
slightly higher net benefit, while the PCPTRC 2.0 showed a slightly
better calibration.46 The difference between these and the Finne,
Chin, Karakiewicz, Sunnybrook, Prostataclass and PCPT 1.0 risk calcu-
lators were further studied in a head-to-head comparison.47 In this
study, the authors did not find any difference in discrimination in the
prediction of any PCa. However, in the prediction of csPCa the
RPCRC showed the most superior discrimination and the highest net
benefit followed by the PCPTRC 2.0. The authors also showed that
offering biopsies if the model-based probability of csPCa was ≥4%,
applying the RPCRC would lead to reduction of 32% of all biopsies
while 5% of all csPCa would not have been detected. For the PCPTRC
2.0, 16% of biopsies would have been reduced while 3% of all csPCa
would not have been detected.
Next to risk stratification using model-based approaches, other
risk stratification tools involve the use of an MRI in case of clinical
suspicion of PCa. However, the role of the MRI as a triage test for the
detection of PCa remains debated. Some authors proposed that a
negative MRI (ie, PI-RADS < 3) of the prostate can be used to refrain
from prostate biopsies.48,49 Men in the Prostate Evaluation for Clini-
cally Important Disease: Sampling Using Image Guidance or Not?
(PRECISION) trial did not receive a biopsy in case of a negative MRI,
which led to a reduction of 28% of all biopsies.50 In this trial, 29% of
all positive PI-RADS lesions were defined as PI-RADS score 3, 40% as
PI-RADS score 4 and 31% as PI-RADS score 5. However, follow-up
data of these men is yet not available so it remains unclear if these
men are actually free from csPCa or whether detection remains in
time. Another study found that 20% of indolent PCa and 3% of csPCa
would not have been detected if biopsies were only offered to men
with a positive MRI.51 In this trial, 13% of all positive PI-RADS lesions
were defined as PI-RADS score 3, 43% as PI-RADS score 4 and 44%
as PI-RADS score 5. The so-called Prostate MR imaging study
(PROMIS) showed that if the MRI would be used as a triage test, 27%
of biopsies could be avoided on basis of a negative MRI at the cost of
not detecting 7% of all Gleason ≥4 + 3 PCa (ISUP grade group ≥ 3) or
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PCa with a maximum cancer core length of ≥6 mm.52 In this trial, 39%
of all positive PI-RADS lesions were defined as PI-RADS score 3, 29%
as PI-RADS score 4 and 32% as PI-RADS score 5. While these trials
showed a considerable amount of reduction in biopsies, MRI cannot
be currently used as the sole triage test, currently available data come
from very different study settings which lead to highly variable perfor-
mance characteristics.53 In addition, interobserver variability and the
fact that MRI is likely to miss tumors of smaller size, with a lower PSA
density, a lower Gleason score, a multifocal appearance, and nonindex
tumors warrants further research.54 While previous studies focused
on finding (cs)PCa, another study suggested that MRI can also be used
to identify indolent PCa.55
Another promising imaging modality which might have a role in
de detection of PCa is the prostate-specific membrane antigen
(PSMA) PET/CT. A retrospective cohort of men with a negative or
contraindications on MRI showed that the PSMA PET/CT was posi-
tive in 56% of all men, of which 44% was diagnosed with any PCa of
which 36% was csPCa.56 However, it should be noted that this study
did not differentiate between men with a negative MRI or men with
contraindications for undergoing MRI, so it cannot be concluded that
the PSMA PET/CT detects tumors missed by MRI. Further evaluation
of the potential of PSMA PET/CT will be done in the prospective PRI-
MARY trial in which men will receive both the PSMA PET/CT and an
MRI.57 However, it should be mentioned that the relative short half-
life of the tracer and the relative higher cost of the image modality as
compared to the MRI can limit the availability of the scan.
Next to risk stratification using an MRI in case of clinical suspicion
of PSA, it has been suggested to incorporate the result of the MRI into
a multivariable prediction model58 or to perform an upfront risk classi-
fication to reduce the number of MRIs. One study referred men with
a risk above the RPCRC threshold of 20% for any PCa and/or 4% for
csPCa and showed that 51% of the MRIs could have been avoided at
the cost of not detecting 25% of all indolent PCa and 10% of all
csPCa.59 In another study including only biopsy naïve men, upfront
risk stratification using the RPCRC would have avoided 37% of all
multiparametric (mp)MRI while missing only 4% csPCa.60 Next to
upfront risk stratification to refer men for MRI, other groups included
the PI-RADS score in their prediction model to estimate the probabil-
ity of PCa. One of those models used age, African American ethnicity,
prior negative biopsy, results of the DRE, PSA and the PI-RADS score
to predict the presence of csPCa at biopsy.61 They found that the dis-
crimination of the model increased from 0.72 to 0.84 when including
PI-RADS score and MRI-derived prostate volume. The authors also
found that compared to biopsying all men with a positive MRI their
model could have avoided 18% of biopsies without missing any
csPCa. This was confirmed by other studies where discrimination
increased with the inclusion of the MRI results in the prediction
model.62-65 One of those studied combined the RPCPC with the
PI-RADSv1.0 score for predicting csPCa, and found for biopsy naïve
men that discrimination increased from 0.81 to 0.83.63 In contrast,
the increase in discrimination was larger for men with previous biopsy,
showing an increase in discrimination from 0.66 to 0.81. Recently, the
RPCRC has been updated to incorporate the results of MRI.65 This
model showed that for men with previous negative biopsy with a risk
threshold of 5% csPCa, 27% of biopsies could have been reduced
while 3% of all csPCa would not have been detected. A risk threshold
of 10% csPCa would lead to a reduction of 36% biopsies while 4% of
all csPCa would not have been detected. However, for biopsy naïve
men this updated risk calculator might be questionable, since, with a
threshold of 5%, only 2% of biopsies would be reduced while missing
15% of csPCa compared offering all men a biopsy with a PSA
≥ 3.0 ng/mL.
All taken together, individualized predictions as an aid at decision
making can assist the physician to select those patients most likely to
benefit from further clinical assessment66 as opposed to the one size
fits all approach. This individualized risk-adapted strategy for the
detection of PCa is recommended by EAU.38,39 To ease interpretation
of a model, it can be visualized in a so-called nomogram67-70 or in
eHealth and mHealth applications, such as RPCRC71 and the PCPTRC
2.072 to ease clinical decision making. In addition, models have been
suggested which incorporate both the probability of aggressive cancer
and the life expectancy to make a recommendation about referral to
the urologist.73,74
2.2 | Biomarkers to aid in risk stratification
Proteomics like, for example, the PSA protein and its subforms can be
detected in both blood and urine. One of those blood-based bio-
markers is the Prostate Health Index (PHI) which combines total, free
and [−2]proPSA into one score. Several studies demonstrated that the
PHI showed better discrimination for (cs)PCa than PSA75-82 and even
better discrimination was observed for PHI density.83 For example, in
one study, the discrimination for detecting csPCa was 0.71 for PHI,
compared to 0.55 for total PSA.81 Also, the same study showed that
offering biopsy for men with a PHI cut-off above 28.6 would have
avoided 30% of biopsies while 5% of Gleason ≥ 7 (ISUP grade group
≥ 2) would not have been detected. In addition, a multicenter
European and Asian study showed that the effect of PHI differed
between cohorts: for European centers, the discrimination for
predicting Gleason ≥3 + 4 (ISUP grade group ≥ 2) was 0.63 for PSA
and 0.71 for PHI, while this was for Asian centers 0.54 for PSA and
0.84 for PHI.75 That same study also showed that a similar sensitivity
of 90% was reached in European centers with a PHI cut-off of 40 in
which 40% of biopsies could have been reduced while 10% csPCa
would not have been detected. In Asian centers, this 90% sensitivity
was reached with a PHI cut-off of 30 in which 56% of biopsies could
have been reduced while 11% csPCa would not have been detected,
suggesting that regional differences should be taken into account.
Other studies have shown that PHI can improve the discrimination of
the RPCRC,84,85 and the PCPTRC 2.0.85 In the latter study, the dis-
crimination of the PCPTRC 2.0 for csPCa increased from 0.58 to 0.70
with PHI; the discrimination of the RPCRC increased from 0.65 to
0.71.85 Finally, studies have shown that PHI next to MRI have led to
better discrimination for csPCa as shown in an Asian population86 and
in the United Kingdom.87 The advantage of the PHI test is that it is
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based on a blood test without the need of clinical variables, and is rel-
atively cheap with prices between 30 and 90 euro.35,88
Next to PHI, another available biomarker panel for the detection
of PCa is the 4-kallikrein (4K) score which is next to the clinical vari-
ables age, and DRE based on total, free, and intact PSA, kallikrein-
related peptidase 2 (hK2), and was updated to include the history of
previous biopsy. The discrimination of a model predicting any PCa
including age, total PSA, and DRE increased from 0.72 to 0.84 with
the addition of free PSA, intact PSA and hK2.89 However, effects for
csPCa were minimal as the discrimination increased from 0.87 to
0.90. In contrast, another study showed that discrimination of csPCa
increased for screening naïve men from 0.68 to 0.80 with the addition
of the 4K score in the model and from 0.72 to 0.83 for men with pre-
vious screening.90 This model showed that for screening naïve men
74% of all biopsies could be reduced if biopsies were offered from a
model-based probability of 20% but this would lead to 26% csPCa not
being detected; for previous screened men, 41% of biopsies could be
reduced in which only 2% of csPCa would not be detected. While the
former studies showed that the 4K score should be preferred over a
model without the 4K score, other studies did not find that the 4K
score showed a better discrimination than PHI91 or the RPCRC includ-
ing cribriform growth in the definition of csPCa.92
Another type of blood-based biomarkers for the detection of (cs)
PCa is based on microRNAs (miRNA). There are over 50 miRNAs iden-
tified, but an essay is not yet implemented in clinical practice.93,94 It
was previously demonstrated that a model with both miRNAs and
PSA improved prediction compared to PSA alone.95 However, valida-
tion of miRNA studies are yet lacking and larger studies are needed
before miRNA can be considered in the clinical setting.96 In addition,
head-to-head comparisons with other prediction models and bio-
markers are needed to assess the superiority of miRNA essays.
Next to blood-based biomarkers, urine-based biomarkers are also
available. One of those urine-based biomarkers is prostate cancer
gene 3 (PCA3) which is calculated as the ratio of the PCA3 mRNA and
PSA mRNA in urine voided after DRE. The discrimination for any PCa
pooled over 46 studies was 0.75,97 which is better than total
PSA,98-100 but lower compared to PHI.101-103 However, another study
showed that there was no difference in discrimination for any PCa
using only the PCA3 or only the PHI.104 Discrimination of the model
increased significantly from 0.71 to 0.77 with both PCA3 and PHI in
the model.
Another urine-based biomarker is SelectMDx which was initially
based on the proteins HOXC6, TDRD1 and DLX1 and showed a
discrimination for csPCa of 0.77, which was higher than PCA3 alone
(0.68) or PSA alone (0.72).105 Combing the HOXC6 and TDRD1 and
DLX1 with PSA showed an increase discrimination of 0.81. A valida-
tion study of these markers showed that the protein TDRD1 actu-
ally did not improve discrimination, but that discrimination was
improved when including information like PSA density and having
had a previous biopsy. The discrimination increased significantly
from 0.81 to 0.86.106 In the same study, it was also shown that the
SelectMDx score outperformed the PCPTRC 2.0 and the PCPTC 2.0
with PCA3. More recently, it was shown that the SelectMDx score
was positively related to the PI-RADS score, but unfortunately, the
authors did not report the discriminative ability of a model con-
taining both the information from SelectMDx and the PI-RADS
score.107
One of the latest developed multivariable risk models is the
so-called Stockholm 3 (STHLM3) risk-based model. This model pre-
dicts the probability of csPCa based on a combination of plasma pro-
tein biomarkers, genetic single nucleotide polymorphisms (SNPs), and
clinical variables.108 In that development study, they showed that the
discrimination of csPCa with total PSA was 0.56, which increased with
additional information from risk factors (age, family history, the pres-
ence of previous biopsies) to 0.58, and with the addition of bio-
markers (one genetic score for all SNPs, beta-microseminoprotein,
macrophage inhibitory cytokine 1, free PSA, intact PSA and hK2), to
0.70, which further increased to 0.74 with the addition of DRE and
prostate volume. This model showed that offering biopsies if the
model probability was ≥10%, 32% for all biopsies would have been
reduced, 44% of benign biopsies would have been detected, and 17%
of indolent PCa would not have been detected without missing any
csPCa compared to offering a biopsy in all men with PSA
≥3 ng/mL. However, all biomarkers were added to the model in one
step which makes it impossible to disentangle the unique effects of
every single biomarker.109 The application of the STHLM3 in current
clinical practice in Sweden showed that with this model based thresh-
old of 10%, 53% of biopsies and 76% of benign biopsies would have
been reduced.110 Other research studied the effect of the STHLM3
and MRI.111 In this study, they showed that men with a positive
STHLM3 and a positive MRI with systematic biopsies, 38% of all biop-
sies could have been reduced in which 8% of all csPCa could have
been missed compared to only MRI (including systematic biopsies)
approach.
All taken together, there are several biomarkers available. At the
moment, it is impossible to draw conclusions on superiority for the
detection of csPCa since head-to-head comparisons comprising both
multivariable models and biomarkers are lacking. The conclusion we
can, however, make from these studies is the fact that all multivari-
able approaches outperform a PSA-based strategy in reducing
unnecessary biopsies and overdiagnosis, see Figure 1 and Table 1.
According to Figure 1, a men with clinical suspicion can either
undergo univariable risk stratification including a PSA measurement
or risk stratification solely on MRI, or multivariable risk stratification
including risk calculators with or without MRI or proteomics and
genomics. This clinical suspicion can originate from urinary com-
plains, family history of PCa or the wish of the patient. We favor the
use of multivariable risk stratification over an univariable approach
with the currently available tools. Men with low risk according to the
risk stratification should be referred to clinical follow-up or should
be refrained from further clinical follow-up when they are at very
low risk of harboring csPCa. Men with elevated risk according to the
risk stratification should receive targeted and/or systematic biopsies.
If no cancer is found, men should be referred to clinical follow-up,
while men diagnosed with PCa should be referred to treatment
including active surveillance.
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2.3 | Which men are most likely to benefit
from screening
Considering the natural history of PCa, it is clear that screening a man
in his 80s or 90s when comorbidity is an issue is not the way to go. In
a modeling study, it was simulated that a single screening at age
55 would result in 27% overdiagnosis which doubled to 56% for a sin-
gle screening at age 75.112 However, elderly men should not automat-
ically be excluded from screening simply based on age. It has been
shown that men screened for the first, and last time at age 70 to
74 can still be confronted with the diagnosis of csPCa. The risk is
small (approximately 3% with a maximum follow-up of 24 years) but
still despite the high age, 26% of all these men die of PCa.113 This sug-
gests that age is not the only and perhaps not the correct factor to
decide to continue or start screening. To selectively identify elderly
men that are at high risk of being diagnosed and die of PCa, again mul-
tivariable risk stratification including taking into account life expec-
tancy and comorbidities is advised.74
F IGURE 1 Flowchart of men with suspicion of PCa combined with risk stratification [Color figure can be viewed at wileyonlinelibrary.com]
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Next to the issue of screening or not screening elderly men,
there is also the question on when to start screening. The Prostate
Early Detection Study Based on a “Baseline” PSA Value in Young
Men (PROBASE) trial randomized 50 000 men aged 45 at an imme-
diate screening arm or a delayed screening arm at age 50 with
screening intervals based on their “baseline” PSA level.114 The first
results of this trial show that only 14% complied with the invitation
and of the men randomized to immediate screening, only 1.8%
showed a PSA ≥3.0 ng/mL, of which 43% based on a confirmatory
second PSA test had a PSA ≥3.0 ng/mL.115 Updated results of this
trial show similar results; 1.5% of men randomized to immediate
screening showed PSA ≥3.0 ng/mL, of which 53% is confirmed at
repeat PSA testing.116 Of the men with confirmed PSA ≥3.0 ng/mL,
33% of men were diagnosed with PCa, of which 68% was csPCa.
These findings suggest that early detection at age 45 in men with
relatively high PSA values considering their age and thus the
absence of benign prostatic hyperplasia is indicated, especially
since almost 70% of PCa is considered csPCa. Longer follow-up
data will show whether the delay of 5 years is acceptable or not
and whether early detection and subsequent treatment will indeed
reduce suffering and dying from PCa. With the latter preferably
resulting in a higher mortality reduction as is currently seen in the
randomized trials that all started at a higher age.
3 | FUTURE OF SCREENING
We should also mention there are challenges for pathologists to
improve the grading of the PCa.117 In addition, aggressive cancer is
usually defined as ISUP grade group 2, but the aggressiveness of these
tumors is under debate.118,119 Other challenges at the moment are
involved with the use of biparametric MRI as opposed to mpMRI,
although the sensitivity and specificity of the modalities are similar.120
At the moment, there are ongoing several population-based screening
studies next to the previous discussed PROBASE trial in Germany. In
Sweden, two trials are recruiting. The Göteborg prostate cancer
screening 2 (G2) trial recruits men from September 2015 till the end
of 2019.121,122 In this trial, over 40 000 men aged 50 to 60 are ran-
domized between a screening and a control group. In the screening
group, men are randomly assigned into three arms. Men assigned to
the first arm and with a PSA ≥ 3.0 ng/mL will receive standard biop-
sies, DRE, and mpMRI; for men with positive MRI targeted biopsies
will be offered. Men with a PSA is below this threshold will not
receive further testing and will be re-invited. Men assigned to the sec-
ond arm and a PSA ≥ 3.0 ng/mL will only receive targeted biopsies in
case of a positive MRI and no systematic biopsies; men with a nega-
tive MRI will be re-invited. Men assigned to the third arm and a PSA
cut-off ≥1.8 ng/mL will only receive targeted biopsies and no
TABLE 1 Summary of key results of various decision-making approaches
Risk stratification tools (cut-off) Setting References
Reduced
biopsies (%)
Reduced
indolent
PCa
diagnosis (%)
Missed
csPCa (%)
Univariable
PSA test (≥3.0 ng/mL)a Population based screening 5, 9, 12, 15, 16 N/A N/A N/A
MRI in triage setting
(≥PI-RADS 3)
Clinical suspicion 50-52 27-29 20 3-7
Multivariable
RPCRC (compared to PSA
≥3.0 ng/mL)
Clinical suspicion + biopsy naive 41 33 14 7
RPCRC (compared to PSA
≥3.0 ng/mL)
Clinical suspicion + prior
negative biopsy
41 37 16 9
RPCRC (≥4%) Clinical suspicion 47 32 25 5
PCPTRC 2.0 (≥4%) Clinical suspicion 47 16 15 3
RPCRC + MRI (≥5%) Clinical suspicion + biopsy naive 65 2 10 15
RPCRC + MRI (≥5%) Clinical suspicion + prior
negative biopsy
65 27 14 3
PHI (90% sensitivity) Clinical suspicion 75, 81 30-56 31-33 5–11
4K score (≥20%) Clinical suspicion + biopsy naive 90 74 38 26
4K score (≥20%) Clinical suspicion + prior
negative biopsy
90 41 73 2
STHLM3 risk-based model
(≥10%)
Clinical suspicion 108, 110 32-53 17-76 0
Note: Head to head comparisons cannot be made based on the data in this table and performance of risk stratification tools should be confirmed in an
external validation.
aIn the population-based screening studies there were no biopsies performed if the PSA was lower than 3.0 ng/mL. Therefore, it is not possible to assess
the missed cancers following this strategy.
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systematic biopsies. All men assigned to the second and third arm
with a PI-RADS 5 will undergo both systematic biopsies and targeted
biopsies. Re-invitation interval is based on the PSA level: men with a PSA
< 0.6 ng/mL will be re-invited 8 years later, men with a PSA between 0.6
and 1.19 ng/mL will be re-invited 4 years later and men with a PSA
between 1.2 and 2.99 ng/mL will be invited after 2 years (see recent
changes in amendment 2, https://www.g2screening.se/wp-content/
uploads/2019/12/Amendment-2.pdf). Men will be invited twice, after
which men with a PSA ≤ 0.59 ng/mL will be screened until they reach
the age of 62, men with a PSA between 0.60 and 1.19 ng/mL will be
screened until they reach the age of 65, men with a PSA between 1.2
and 1.79 ng/mL will be screened until they reach the age of 70, and men
with a PSA above 1.8 ng/mL will be screened until they reach the age
75 (see recent changes in amendment 10, https://www.g2screening.se/
wp-content/uploads/2020/02/Amendment-10.pdf). Nonattenders will
be re-invited after 3 months and after 9 months. The primary outcome
of this trial is the rate of overdiagnosis, defined as small insignificant
tumors that would never be detected within one's life without screening.
Another population-based screening study in Sweden is the
STHLM3-MR Phase 2 trial.123 In this trial, 25 000 men aged 50-74 will
be invited and men with an elevated risk will be randomized. The PSA
and STHLM-3 test define elevated risk: a PSA ≥3 ng/mL or a PSA
≥1.5 ng/mL with STHLM3 > 11%. Men will be randomized in a 2 (con-
trol arm): 3 (experimental) ratio. Men in the control arm will receive
only systematic biopsies and men in the experimental arm will receive
an MRI. Men with a positive MRI will receive both targeted and sys-
tematic biopsies; men with a negative MRI will receive systematic
biopsies if the STHLM3 test is ≥25%, or no biopsies if the
STHLM3 < 25%. Primary outcome in this trial is the number of
detected csPCa and indolent PCa between the diagnostic pathways.
In Finland, the ProScreen trial which started in 2018 randomized
67 000 men aged 55-67.124 Randomization is in a 1 (screening arm):
3 (control arm) ratio. Men in the screening arm will be offered PSA
test; men with a PSA ≥ 3.0 ng/mL will receive an additional 4K test.
Men with increased risk (ie, 4K score ≥ 7.5) will undergo mpMRI.
Biopsies will only be taken in men with a positive MRI. Men with a
positive screening (ie, PSA ≥3.0 ng/mL) will be re-invited every
2 years until they complete five screening rounds. Men with a nega-
tive screening and a PSA between 1.5 and 3.0 ng/mL will be re-invited
after 5 to 6 years and after 9 to 10 years. Men with PSA below
1.5 ng/mL will be re-invited after 7 to 8 years. The primary outcome
of this trial is PCa mortality.
4 | CONCLUSION
In Europe, PSA-based screening showed a relative reduction of PCa
mortality of 20%. However, this was accompanied by a substantial
amount of overdiagnosis and unnecessary biopsies. In the past years,
a large variety of tools has been developed to allow an individualized
approach to select patients who would benefit from further clinical
assessment. These risk stratification tools have shown to be able to
reduce the number of biopsies and overdiagnosis, but head-to-head
comparisons are lacking making it impossible to draw conclusions on
the superiority of these tools. Current population-based screening
studies are using a multivariable individualized approach with the aim
to maintain reduction of PCa mortality and to reduce the number of
biopsies and overdiagnosis. These trials will lead to new insights in the
field of population-based screening for PCa. It is however not advis-
able to await these results and continue opportunistic screening activ-
ities based on PSA alone. Current guidelines based on contemporary
knowledge should be implemented in clinical practice and decision
making without delay.125
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